Patents by Inventor Adriana Ingrid Velter

Adriana Ingrid Velter has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BRANCHED MACROCYCLIC 4-(PYRAZOL-5-YL)-INDOLE DERIVATIVES AS INHIBITORS OF MCL-1
    Publication number: 20240124487
    Abstract: The present invention relates to pharmaceutical agents of formula (I) useful for therapy and/or prophylaxis in a subject, pharmaceutical composition comprising such compounds, and their use as MCL-1 inhibitors, useful for treating diseases such as cancer.
    Type: Application
    Filed: December 16, 2021
    Publication date: April 18, 2024
    Inventors: Frederik Jan Rita ROMBOUTS, Adriana-Ingrid VELTER, Petrus Jacobus Johannes Antonius BUIJNSTERS, Sofia FERRER CABRERA
  • MACROCYCLIC 7-PYRAZOL-5-YL-INDOLE DERIVATIVES AS INHIBITORS OF MCL-1
    Publication number: 20230265105
    Abstract: The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a subject, pharmaceutical composition comprising such compounds, and their use as MCL-1 inhibitors, useful for treating diseases such as cancer.
    Type: Application
    Filed: May 27, 2021
    Publication date: August 24, 2023
    Inventors: Frederik Jan Rita ROMBOUTS, Aldo PESCHIULLI, Samuël Dominique DEMIN, Adriana-Ingrid VELTER, Matthieu Dominique JOUFFROY
  • MACROCYCLIC ETHER CONTAINING INDOLE DERIVATIVES AS INHIBITORS OF MCL-1
    Publication number: 20230250109
    Abstract: The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a subject, pharmaceutical composition comprising such compounds, and their use as MCL-1 inhibitors, useful for treating diseases such as cancer.
    Type: Application
    Filed: July 8, 2021
    Publication date: August 10, 2023
    Inventors: Benoît Christian Albert Ghislain DE BOECK, Petrus Jacobus Johannes Antonius BUIJNSTERS, Sofia FERRER CABRERA, Aldo PESCHIULLI, Tristan REUILLON, Frederik Jan Rita ROMBOUTS, Adriana-Ingrid VELTER
  • N-LINKED MACROCYCLIC 7-(PYRAZOL-5-YL)-INDOLE DERIVATIVES AS INHIBIORS OF MCL-1
    Publication number: 20230234969
    Abstract: The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a subject, pharmaceutical composition comprising such compounds, and their use as MCL-1 inhibitors, useful for treating diseases such as cancer.
    Type: Application
    Filed: June 18, 2021
    Publication date: July 27, 2023
    Inventors: Frederik Jan Rita ROMBOUTS, Benoit Christian Albert Ghislain DE BOECK, Aldo PESCHIULLI, Adriana-Ingrid VELTER
  • N-LINKED MACROCYCLIC 4-(PYRAZOL-5-YL)-INDOLE DERIVATIVES AS INHIBITORS OF MCL-1
    Publication number: 20230234965
    Abstract: The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a subject, pharmaceutical composition comprising such compounds, and their use as MCL-1 inhibitors, useful for treating diseases such as cancer.
    Type: Application
    Filed: June 18, 2021
    Publication date: July 27, 2023
    Inventors: Aldo PESCHIULLI, Frederik Jan Rita ROMBOUTS, Adriana-Ingrid VELTER
  • MACROCYCLIC INDOLE DERIVATIVES AS INHIBITORS OF MCL-1
    Publication number: 20230130109
    Abstract: The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a subject, pharmaceutical composition comprising such compounds, and their use as MCL-1 inhibitors, useful for treating diseases such as cancer.
    Type: Application
    Filed: February 18, 2021
    Publication date: April 27, 2023
    Inventors: Frederik Jan Rita ROMBOUTS, Tristan REUILLON, Aldo PESCHIULLI, Adriana-Ingrid VELTER, Ann Marleen VOS
  • OGA INHIBITOR COMPOUNDS
    Publication number: 20230099293
    Abstract: The present invention relates to O-GlcNAc hydrolase (OGA) inhibitors. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which inhibition of OGA is beneficial, such as tauopathies, in particular Alzheimer's disease or progressive supranuclear palsy; and neurodegenerative diseases accompanied by a tau pathology, in particular amyotrophic lateral sclerosis or frontotemporal lobe dementia caused by C9ORF72 mutations.
    Type: Application
    Filed: December 18, 2020
    Publication date: March 30, 2023
    Applicant: JANSSEN PHARMACEUTICA NV
    Inventors: José Manuel BARTOLOMÉ-NEBREDA, Petrus Jacobus Johannes Antonius BUIJNSTERS, Ana Isabel DE LUCAS OLIVARES, Joseph Elisabeth LEENAERTS, Carolina MARTINEZ LAMENCA, Daniel OEHLRICH, Andrés Avelino TRABANCO-SUÁREZ, Yves Emiel M VAN ROOSBROECK, Adriana Ingrid VELTER
  • OGA INHIBITOR COMPOUNDS
    Publication number: 20230058733
    Abstract: The present invention relates to O-GlcNAc hydrolase (OGA) inhibitors. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which inhibition of OGA is beneficial, such as tauopathies, in particular Alzheimer's disease or progressive supranuclear palsy; and neurodegenerative diseases accompanied by a tau pathology, in particular amyotrophic lateral sclerosis or frontotemporal lobe dementia caused by C9ORF72 mutations; or alpha synucleinopathies, in particular Parkinson's disease, dementia due to Parkinson's (or neurocognitive disorder due to Parkinson's disease), dementia with Lewy bodies, multiple system atrophy, or alpha synucleinopathy caused by Gaucher's disease.
    Type: Application
    Filed: December 18, 2020
    Publication date: February 23, 2023
    Applicant: JANSSEN PHARMACEUTICA NV
    Inventors: José Manuel BARTOLOMÉ-NEBREDA, Petrus Jacobus Johannes Antonius BUIJNSTERS, Joseph Elisabeth LEENAERTS, Carolina MARTINEZ LAMENCA, Daniel OEHLRICH, Andrés Avelino TRABANCO-SUÁREZ, Yves Emiel M VAN ROOSBROECK, Adriana Ingrid VELTER
  • [1,2,4]triazolo[1,5-a]pyrimidine compounds as PDE2 inhibitors
    Patent number: 11319321
    Abstract: The present invention relates to novel [1,2,4]triazolo[1,5-a]pyrimidin-yl derivatives as inhibitors of phosphodiesterase 2 (PDE2). The invention is also directed to pharmaceutical compositions comprising the compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which PDE2 is involved, such as neurological and psychiatric disorders.
    Type: Grant
    Filed: October 31, 2017
    Date of Patent: May 3, 2022
    Assignee: Janssen Pharmaceutica NV
    Inventors: Yves Emiel Maria Van Roosbroeck, Frans Alfons Maria Van den Keybus, Adriana Ingrid Velter, Petrus Jacobus Johannes Antonius Buijnsters, Gary John Tresadern, Henricus Jacobus Maria Gijsen
  • OGA INHIBITOR COMPOUNDS
    Publication number: 20210277003
    Abstract: The present invention relates to O-GlcNAc hydrolase (OGA) inhibitors. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which inhibition of OGA is beneficial, such as tauopathies, in particular Alzheimer's disease or progressive supranuclear palsy; and neurodegenerative diseases accompanied by a tau pathology, in particular amyotrophic lateral sclerosis or frontotemporal lobe dementia caused by C9ORF72 mutations.
    Type: Application
    Filed: June 20, 2019
    Publication date: September 9, 2021
    Inventors: José Manuel Bartolomé-Nebreda, Andrés Avelino Trabanco-Suárez, Carolina Martinez Lamenca, Joseph Elisabeth Leenaerts, Daniel Oehlrich, Petrus Jacobus Johannes Antonius Buijnsters, Adriana Ingrid Velter, Yves Emiel Maria Van Roosbroeck
  • OGA INHIBITOR COMPOUNDS
    Publication number: 20210130352
    Abstract: The present invention relates to O-GlcNAc hydrolase (OGA) inhibitors. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which inhibition of OGA is beneficial, such as tauopathies, in particular Alzheimer's disease or progressive supranuclear palsy; and neurodegenerative diseases accompanied by a tau pathology, in particular amyotrophic lateral sclerosis or frontotemporal lobe dementia caused by C9ORF72 mutations.
    Type: Application
    Filed: June 20, 2019
    Publication date: May 6, 2021
    Inventors: José Manuel Bartolomé-Nebreda, Andrés Avelino Trabanco-Suárez, Joseph Elisabeth Leenaerts, Daniel Oehlrich, Petrus Jacobus Johannes Antonius Buijnsters, Carolina Martinez Lamenca, Adriana Ingrid Velter, Yves Erniel Maria Van Roosbroeck
  • [1,2,4]triazolo[1,5and#8208;A]pyrimidine compounds as PDE2 inhibitors
    Patent number: 10947242
    Abstract: The present invention relates to novel [1,2,4]triazolo[1,5-a]pyrimidin-yl derivatives as inhibitors of phosphodiesterase 2 (PDE2). The invention is also directed to pharmaceutical compositions comprising the compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which PDE2 is involved, such as neurological and psychiatric disorders.
    Type: Grant
    Filed: October 31, 2017
    Date of Patent: March 16, 2021
    Assignee: Janssen Pharmaceutica, NV
    Inventors: Yves Emiel Maria Van Roosbroeck, Frans Alfons Maria Van den Keybus, Gary John Tresadern, Petrus Jacobus Johannes Antonius Buijnsters, Adriana Ingrid Velter, Edgar Jacoby, Gregor James Macdonald, Henricus Jacobus Maria Gijsen, Abdellah Ahnaou, Wilhelmus Helena Ignatius Maria Drinkenburg
  • [1,2,4]TRIAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AS PDE2 INHIBITORS
    Publication number: 20200055858
    Abstract: The present invention relates to novel [1,2,4]triazolo[1,5-a]pyrimidin-yl derivatives as inhibitors of phosphodiesterase 2 (PDE2). The invention is also directed to pharmaceutical compositions comprising the compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which PDE2 is involved, such as neurological and psychiatric disorders.
    Type: Application
    Filed: October 31, 2017
    Publication date: February 20, 2020
    Applicant: Janssen Pharmaceutica NV
    Inventors: Yves Emiel Maria Van Roosbroeck, Frans Alfons Maria Van den Keybus, Adriana Ingrid Velter, Petrus Jacobus Johannes Antonius Buijnsters, Gary John Tresadern, Henricus Jacobus Maria Gijsen
  • Substituted 3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-diones as gamma secretase modulators
    Patent number: 10562897
    Abstract: The present invention is concerned with novel substituted pyrido-piperazinone derivatives of Formula (I) wherein R1, R2, R3, R4, R5, L, Z and X have the meaning defined in the claims. The compounds according to the present invention are useful as gamma secretase modulators. The invention further relates to processes for preparing such novel compounds, pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.
    Type: Grant
    Filed: July 18, 2018
    Date of Patent: February 18, 2020
    Assignee: JANSSEN PHARMACEUTICA NV
    Inventors: François Paul Bischoff, Adriana Ingrid Velter, Frederik Jan Rita Rombouts, Michel Anna Jozef De Cleyn, Sven Franciscus Anna Van Brandt, Henricus Jacobus Maria Gijsen, Chiara Zavattaro, Frans Alfons Maria Van den Keybus
  • [1,2,4]TRIAZOLO[1,5‐A]PYRIMIDINE COMPOUNDS AS PDE2 INHIBITORS
    Publication number: 20190276462
    Abstract: The present invention relates to novel [1,2,4]triazolo[1,5-a]pyrimidin-yl derivatives as inhibitors of phosphodiesterase 2 (PDE2). The invention is also directed to pharmaceutical compositions comprising the compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which PDE2 is involved, such as neurological and psychiatric disorders.
    Type: Application
    Filed: October 31, 2017
    Publication date: September 12, 2019
    Applicant: Janssen Pharmaceutica NV
    Inventors: Yves Emiel Maria Van Roosbroeck, Frans Alfons Maria Van den Keybus, Gary John Tresadern, Petrus Jacobus Johannes Buijnsters, Adriana Ingrid Velter, Edgar JACOBY, Gregor James Macdonald, Henricus Jacobus Maria Gijsen, Abdellah Ahnaou, Wihelmus Helena lgnatius Drinkenburg
  • Substituted 3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-diones as gamma secretase modulators
    Patent number: 10246454
    Abstract: The present invention is concerned with novel substituted pyrido-piperazinone derivatives of Formula (I) wherein R1, R2, R3, R4, R5, L, Z and X have the meaning defined in the claims. The compounds according to the present invention are useful as gamma secretase modulators. The invention further relates to processes for preparing such novel compounds, pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.
    Type: Grant
    Filed: January 16, 2014
    Date of Patent: April 2, 2019
    Assignee: JANSSEN PHARMACEUTICA NV
    Inventors: François Paul Bischoff, Adriana Ingrid Velter, Frederik Jan Rita Rombouts, Michel Anna Jozef De Cleyn, Sven Franciscus Anna Van Brandt, Henricus Jacobus Maria Gijsen, Chiara Zavattaro, Frans Alfons Maria Van den Keybus
  • NOVEL SUBSTITUTED PYRIDO-PIPERAZINONE DERIVATIVES AS GAMMA SECRETASE MODULATORS
    Publication number: 20180319797
    Abstract: The present invention is concerned with novel substituted pyrido-piperazinone derivatives of Formula (I) wherein R1, R2, R3, R4, R5, L, Z and X have the meaning defined in the claims. The compounds according to the present invention are useful as gamma secretase modulators. The invention further relates to processes for preparing such novel compounds, pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.
    Type: Application
    Filed: July 18, 2018
    Publication date: November 8, 2018
    Inventors: François Paul Bischoff, Adriana Ingrid Velter, Frederik Jan, Rita Rombouts, Michel Anna, Jozef De Cleyn, Sven Franciscus, Anna Van Brandt, Henricus Jacobus, Maria Gijsen, Chiara Zavattaro, Frans Alfons, Maria Van den Keybus
  • NOVEL SUBSTITUTED PYRIDO-PIPERAZINONE DERIVATIVES AS GAMMA SECRETASE MODULATORS
    Publication number: 20150353544
    Abstract: The present invention is concerned with novel substituted pyrido-piperazinone derivatives of Formula (I) wherein R1, R2, R3, R4, R5, L, Z and X have the meaning defined in the claims. The compounds according to the present invention are useful as gamma secretase modulators. The invention further relates to processes for preparing such novel compounds, pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.
    Type: Application
    Filed: January 16, 2014
    Publication date: December 10, 2015
    Applicant: Janssen Pharmaceutica NV
    Inventors: François Paul Bischoff, Adriana Ingrid Velter, Frederik Jan, Rita Rombouts, Michel Anna, Jozef De Cleyn, Sven Franciscus, Anna Van Brandt, Henricus Jacobus, Maria Gijsen, Chiara Zavattaro, Frans Alfons, Maria Van den Keybus
  • Substituted pyrido[1,2-a]pyrazines and substituted pyrido[1,2-a][1,4]diazepines for the treatment of (inter alia) Alzheimer's disease
    Patent number: 9181245
    Abstract: The present invention is concerned with novel substituted 3,4-dihydro-2H-pyrido[1,2- a]pyrazine-1,6-dione derivatives of Formula (I) wherein R1, R2, R3, R4, R5, Z and X have the meaning defined in the claims. The compounds according to the present invention are useful as gamma secretase modulators. The invention further relates to processes for preparing such novel compounds, pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.
    Type: Grant
    Filed: May 16, 2013
    Date of Patent: November 10, 2015
    Assignees: Janssen Pharmaceuticals, Inc., Cellzome Limited
    Inventors: Frederik Jan Rita Rombouts, Andrés Avelino Trabanco-Suarez, Henricus Jacobus Maria Gijsen, Gregor James MacDonald, François Paul Bischoff, Sergio-Alvar Alonso-de-Diego, Adriana Ingrid Velter, Yves Emiel Maria Van Roosbroeck
  • Substituted indole derivatives as gamma secretase modulators
    Patent number: 9115143
    Abstract: The present invention is concerned with novel substituted indole derivatives of Formula (I) wherein R1, R2, R3, A1, A2, A3, Y and X have the meaning defined in the claims. The compounds according to the present invention are useful as gamma secretase modulators. The invention further relates to processes for preparing such novel compounds, pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.
    Type: Grant
    Filed: July 12, 2012
    Date of Patent: August 25, 2015
    Assignees: Janssen Pharmaceuticals, Inc., Cellzome Limited
    Inventors: Garrett Berlond Minne, François Paul Bischoff, Henricus Jacobus Maria Gijsen, Adriana Ingrid Velter, Serge Maria Aloysius Pieters, Didier Jean-Claude Berthelot